MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company DPO Ratio 2011-2026 | BMY
Annual DPO Ratio Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94 | 89.6 | 108 | 108 | 104 | 80 | 110 | 105 | 135 | 123 | 146 | 231 | 202 | 174 | 170 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 231 | 80 | 132 |
Quarterly DPO Ratio Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 128 | 112 | 111 | 102 | 98.8 | 107 | 99.4 | 111 | - | 50.3 | 49.4 | 109 | - | 126 | 122 | 91.3 | - | 99 | 91.7 | 64.3 | - | 125 | 113 | 108 | - | 105 | 106 | 119 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 128 | 49.4 | 102 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B |  USA |
 |
Alnylam Pharmaceuticals
ALNY
|
55 | $ 320.13 | -3.98 % | $ 41.9 B | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 21.81 | 0.6 % | $ 1.02 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Akebia Therapeutics
AKBA
|
168 | $ 1.35 | -12.9 % | $ 347 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
395 | $ 4.26 | 0.47 % | $ 456 M | USA |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 24.19 | -1.59 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.61 | 8.05 % | $ 428 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
BioXcel Therapeutics
BTAI
|
34.2 K | $ 1.07 | 1.9 % | $ 13.1 M | USA |
 |
ChromaDex Corporation
CDXC
|
76.3 | - | -0.88 % | $ 598 M | USA |